# NLS PHARMACEUTICS LTD (NLSP)

> Institutional ownership reported to the SEC as of Q3 2025, from Form 13F filings. Source: https://holderbook.com/stocks/NLSP/

- Reporting holders: 3
- Reported value: $263.1K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [BVF INC/IL](https://holderbook.com/funds/1056807-bvf-inc-il/) | $262.9K | 143,676 | 0.0% | 5 |
| [UBS Group AG](https://holderbook.com/funds/1610520-ubs-group-ag/) | $70 | 38 | 0.0% | 5 |
| [CoreCap Advisors, LLC](https://holderbook.com/funds/1902501-corecap-advisors-llc/) | $66 | 36 | 0.0% | 2 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2025 | 3 | $263.1K |
| Q2 2025 | 4 | $467.5K |
| Q1 2025 | 2 | $260.9K |
| Q4 2024 | 2 | $320.7K |
| Q3 2024 | 2 | $752.4K |
| Q2 2024 | 9 | $1.8M |
| Q1 2024 | 7 | $1.5M |
| Q4 2023 | 5 | $3.4M |
| Q3 2023 | 7 | $4.4M |
| Q2 2023 | 9 | $7.1M |
| Q1 2023 | 7 | $9.6M |
| Q4 2022 | 4 | $7.5M |